One in three bacterial infections reported across the WHO South-East Asian and Eastern Mediterranean regions were resistant to antibiotic treatment in 2023. More than 40% of E. coli and over 55% of Klebsiella pneumoniae are now resistant to third-generation cephalosporins, moving demand toward carbapenems, beta-lactam inhibitor combinations and the reserve-class injectables behind them.
222 of these 473 lines are sterile injectables, including the lyophilised reserve-class presentations that hospital and tender supply runs on.
Range depth
Used when first- and second-line therapy has failed.
34 sulbactam and tazobactam pairings across the range.
All three are lyophilised presentations.
High-value orals moving through donor, tender and private channels.
We establish what is already registered in your market, who supplies it today, and where demand is going unmet.
We set your current range against the portfolio and separate genuine gaps from lines you already stock.
You get the molecules in filing order, which of them need a dossier built for your authority, and which fall outside the range.
We compile the dossier in CTD format for your authority and supply the COPP and plant-level WHO-GMP and PIC/S certificates behind it.
We analyse your market and set your existing range against the portfolio, then return the molecules worth filing in priority order with the documentation route for each.